Spots Global Cancer Trial Database for metastatic malignant solid neoplasm

Every month we try and update this database with for metastatic malignant solid neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer	NCT05058339	Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig...	Survey Administ...	18 Years -	M.D. Anderson Cancer Center
NCI COVID-19 in Cancer Patients, NCCAPS Study	NCT04387656	COVID-19 Infect... Hematopoietic a... Malignant Solid... Metastatic Mali...	Biospecimen Col... Data Collection Quality-of-Life... Questionnaire A...	-	National Cancer Institute (NCI)
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	NCT04233567	Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali...	Infigratinib	18 Years -	Ohio State University Comprehensive Cancer Center
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer	NCT02898207	Metastatic High... Metastatic Mali... Metastatic Prim... Metastatic Trip... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Breas... Recurrent High ... Recurrent High ... Recurrent Prima... Recurrent Tripl... Refractory Fall... Refractory Ovar... Refractory Prim... Refractory Trip... Unresectable Hi... Unresectable Ma... Unresectable Pr...	Olaparib Onalespib	18 Years -	National Cancer Institute (NCI)
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02097225	BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So...	Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib	18 Years -	National Cancer Institute (NCI)
Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression	NCT04957615	Metastatic Mali... Unresectable So...	Nivolumab	-	M.D. Anderson Cancer Center
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy	NCT03080883	Cerebral Vein T... Deep Vein Throm... Hematopoietic a... Malignant Solid... Metastatic Mali... Pulmonary Embol... Splanchnic Vein...	Apixaban	18 Years -	Academic and Community Cancer Research United
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy	NCT02710253	Hematopoietic a... Metastatic Mali...	External Beam R... Laboratory Biom... Stereotactic Bo...	18 Years -	M.D. Anderson Cancer Center
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors	NCT04539574	Central Nervous... Glioma Metastatic Mali... Metastatic Mali...	7 Tesla Magneti... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies	NCT02620839	Solid Tumors	Alpelisib Cisplatin	18 Years -	University of California, San Francisco
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	NCT05687110	Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Diagnostic Imag... Novobiocin Sodi...	18 Years -	National Cancer Institute (NCI)
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies	NCT02419495	Advanced Malign... Clinical Stage ... Clinical Stage ... Fallopian Tube ... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Rena... Ovarian Carcino... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Primary Periton... Stage III Lung ... Stage III Renal... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IV Renal ... Stage IVA Lung ... Stage IVB Lung ... Triple-Negative... Unresectable Lu... Unresectable Me... Unresectable Re...	Capecitabine Carboplatin Cyclophosphamid... Doxorubicin Eribulin Fluorouracil Ipilimumab Irinotecan Hydr... Leucovorin Calc... Nivolumab Olaparib Oxaliplatin Paclitaxel Pembrolizumab Pemetrexed Selinexor Topotecan	18 Years -	M.D. Anderson Cancer Center
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	NCT04639245	Anatomic Stage ... Metastatic Lung... Metastatic Mali... Metastatic Trip... Metastatic Urot... Stage IV Lung C...	Atezolizumab Cyclophosphamid... Fludarabine MAGE-A1-specifi... PD1 Inhibitor	18 Years -	Fred Hutchinson Cancer Center
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	NCT04840589	Metastatic Mali... Recurrent Malig... Recurrent Plati... Refractory Ovar...	BET Bromodomain... Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	NCT04388852	Aggressive Vari... Castration-Resi... Metastatic Clea... Metastatic Mali... Metastatic Pros... Metastatic Urot... Stage IV Prosta... Stage IV Renal ... Stage IVA Prost... Stage IVB Prost...	Ipilimumab Valemetostat	18 Years -	M.D. Anderson Cancer Center
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	NCT03590054	Stage III Cutan... Stage IV Cutane... Locally Advance... Locally Advance... Metastatic Head... Metastatic Mali... Metastatic Mela... Metastatic Urot... Non-Small Cell ... Stage IB Lung C... Stage III Cutan... Stage III Lung ... Stage III Urete... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Cutane... Stage IV Lung C... Stage IV Ureter... Stage IVA Lung ... Stage IVB Lung ...	Abexinostat Pembrolizumab	18 Years -	University of California, San Francisco
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02408861	Advanced Malign... Anal Carcinoma HIV Infection Kaposi Sarcoma Lung Carcinoma Metastatic Mali... Recurrent Class... Refractory Clas... Unresectable So...	Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Ipilimumab Nivolumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors	NCT04771520	Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Metastatic Prim... Metastatic Sarc... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Prognostic Stag... Prognostic Stag... Stage IIIC Colo... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color...	Avapritinib	18 Years -	M.D. Anderson Cancer Center
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	NCT06320405	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Axatilimab Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Paclitaxel Positron Emissi... Retifanlimab	18 Years -	OHSU Knight Cancer Institute
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases	NCT05054998	Metastatic Mali... Metastatic Mali...	Fludeoxyglucose... Magnetic Resona... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning	NCT04889144	Locally Advance... Metastatic Mali...	Communication I... Best Practice Questionnaire A...	18 Years -	Fred Hutchinson Cancer Center
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors	NCT04840589	Metastatic Mali... Recurrent Malig... Recurrent Plati... Refractory Ovar...	BET Bromodomain... Biopsy Biospecimen Col... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Positron Emissi... X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	NCT05554380	Locally Advance... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Magnetic Resona... Paclitaxel	18 Years -	National Cancer Institute (NCI)
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis	NCT05059678	Metastatic Mali... Recurrent Malig...	Best Practice Educational Int... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor	NCT04800627	Locally Advance... Metastatic Mali... Unresectable Ma...	Pembrolizumab Pevonedistat	18 Years -	M.D. Anderson Cancer Center
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning	NCT04889144	Locally Advance... Metastatic Mali...	Communication I... Best Practice Questionnaire A...	18 Years -	Fred Hutchinson Cancer Center
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	NCT03872427	Advanced Malign... Metastatic Mali... NF1 Mutation Po... Unresectable Ma...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Pharmacodynamic... Positron Emissi... Telaglenastat H...	18 Years -	National Cancer Institute (NCI)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	NCT03682289	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast...	Ceralasertib Olaparib Durvalumab	18 Years -	University of California, San Francisco
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	NCT04233567	Advanced Malign... Cholangiocarcin... Metastatic Mali... Refractory Mali...	Infigratinib	18 Years -	Ohio State University Comprehensive Cancer Center
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	NCT05564377	Advanced Malign... Anatomic Stage ... Anatomic Stage ... Locally Advance... Malignant Femal... Metastatic HER2... Metastatic Mali... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Unresectable HE... Unresectable Ma...	Alpelisib Binimetinib Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Fulvestrant Ipatasertib Leucovorin Magnetic Resona... Multigated Acqu... Mutation Carrie... Neratinib Malea... Nilotinib Hydro... Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Positron Emissi... Selumetinib Sul... Sotorasib	-	National Cancer Institute (NCI)
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	NCT04119024	Metastatic Mali... Metastatic Mela... Pathologic Stag... Pathologic Stag... Recurrent Malig... Refractory Mali... Uveal Melanoma Acral Melanoma Neuroendocrine ... Paraganglioma Pheochromocytom... Adrenocortical ... Pancreatic Neur... Thyroid Cancer Breast Cancer Lung Adenocarci... Head and Neck S...	Biopsy Biospecimen Col... Computed Tomogr... Cyclophosphamid... Fludarabine Pho... Fludeoxyglucose... IL13Ralpha2-spe... Magnetic Resona... Positron Emissi...	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer	NCT03927885	Advanced Malign... Metastatic Mali... Recurrent Malig...	Placebo Adminis... Quality-of-Life... Questionnaire A... Waiting List	18 Years -	M.D. Anderson Cancer Center
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction	NCT03217253	Ann Arbor Stage... Ann Arbor Stage... Metastatic Mali... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable So...	Laboratory Biom... Pharmacological... Tazemetostat	18 Years -	National Cancer Institute (NCI)
Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases	NCT02387905	Metastatic Mali... Metastatic Mali...	Management of T... Quality-of-Life... Questionnaire A... Stereotactic Ra...	18 Years -	M.D. Anderson Cancer Center
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	NCT04879121	Locally Advance... Metastatic Mali...	Larotrectinib S...	16 Years -	M.D. Anderson Cancer Center
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer	NCT03579446	Hematopoietic a... Malignant Solid... Metastatic Mali...	Hydrocodone Hydromorphone Levorphanol Morphine Oxycodone Oxymorphone Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies	NCT02620839	Solid Tumors	Alpelisib Cisplatin	18 Years -	University of California, San Francisco
Studying TAK-243 in Patients With Advanced Cancer	NCT06223542	Advanced Lympho... Advanced Malign... Metastatic Mali...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... UAE Inhibitor T...	18 Years -	National Cancer Institute (NCI)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer	NCT04673448	Anatomic Stage ... Anatomic Stage ... BRCA-Associated... BRCA-Associated... Metastatic BRCA... Metastatic Brea... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Panc... Metastatic Prim... Prognostic Stag... Prognostic Stag... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Br... Unresectable Fa... Unresectable Ma... Unresectable Ov... Unresectable Pa... Unresectable Pr...	Dostarlimab Niraparib	18 Years -	University of Washington
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	NCT03218826	Advanced Breast... Advanced Malign... Advanced Prosta... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Metastatic Brea... Metastatic Mali... Metastatic Pros... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... Triple-Negative... Unresectable So...	Docetaxel Laboratory Biom... Pharmacological... PI3Kbeta Inhibi...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	NCT05687136	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib	18 Years -	National Cancer Institute (NCI)
Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors	NCT05733949	Metastatic Mali...	Biospecimen Col... Computed Tomogr... Stereotactic Bo...	18 Years -	City of Hope Medical Center
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)	NCT05371132	Metastatic Mali... Lymphoma	Positron Emissi... Stereotactic Bo... Zirconium Zr 89... Intensity Modul...	18 Years -	City of Hope Medical Center
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	NCT04729725	Advanced Malign... Metastatic Mali... Unresectable Ma...	Anti-TGF-beta M... Cemiplimab	18 Years -	M.D. Anderson Cancer Center
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer	NCT02862275	Hematopoietic a... Metastatic Mali... Unresectable Ma...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Testing the Safety of CB-5339 in Patients With Cancer	NCT04372641	Aggressive Non-... Indolent Non-Ho... Locally Advance... Metastatic Mali...	p97 Inhibitor C...	18 Years -	National Cancer Institute (NCI)
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery	NCT03184038	Metastatic Mali... Metastatic Mali...	Cognitive Asses... Stereotactic Ra... Stereotactic Bo... Quality-of-Life...	18 Years -	Thomas Jefferson University
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	NCT04329494	Clinical Stage ... Clinical Stage ... Clinical Stage ... Malignant Uteri... Metastatic Appe... Metastatic Colo... Metastatic Gast... Metastatic Mali... Metastatic Mali... Metastatic Ovar... Pathologic Stag... Peritoneal Carc... Postneoadjuvant... Stage IV Append... Stage IV Colore... Stage IV Ovaria... Stage IV Uterin... Stage IVA Appen... Stage IVA Color... Stage IVA Ovari... Stage IVA Uteri... Stage IVB Appen... Stage IVB Color... Stage IVB Ovari... Stage IVB Uteri... Stage IVC Appen... Stage IVC Color...	Biopsy Cisplatin Doxorubicin Fluorouracil Intraperitoneal... Irinotecan Leucovorin Mitomycin Oxaliplatin Quality-of-Life... Questionnaire A...	18 Years -	City of Hope Medical Center
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	NCT01822522	Advanced Malign... HIV Infection Metastatic Mali... Recurrent Malig... Unresectable So...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors	NCT05687136	Advanced Malign... Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Peposertib Positron Emissi... Tuvusertib	18 Years -	National Cancer Institute (NCI)
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment	NCT05455606	Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali...	Best Practice Chart Abstracti... Educational Int... Genomic Profile Interview Questionnaire A... Tumor Board Rev...	18 Years -	SWOG Cancer Research Network
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors	NCT02079740	Metastatic Mali... Refractory Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib	18 Years -	National Cancer Institute (NCI)
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)	NCT05638295	Advanced Malign... Metastatic Mali...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Panitumumab Sotorasib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	NCT03428802	BRCA1 Gene Muta... BRCA2 Gene Muta... Locally Advance... Metastatic Mali... POLD1 Gene Muta... POLE Gene Mutat... Recurrent Malig... Recurrent Ovari... Stage III Breas... Stage III Ovari... Stage IIIA Brea... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Laboratory Biom... Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	NCT04693468	Advanced Malign... Metastatic Mali... Recurrent Malig...	Axitinib Crizotinib Palbociclib Ise... Talazoparib Tos...	18 Years -	M.D. Anderson Cancer Center
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer	NCT03579446	Hematopoietic a... Malignant Solid... Metastatic Mali...	Hydrocodone Hydromorphone Levorphanol Morphine Oxycodone Oxymorphone Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors	NCT03030378	Metastatic Mali... Unresectable Ma...	Biopsy Biospecimen Col... Computed Tomogr... Edodekin alfa Magnetic Resona... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	NCT05010096	Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig...	Copanlisib Elimusertib	18 Years -	M.D. Anderson Cancer Center
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer	NCT02298959	Clinical Stage ... Metastatic Colo... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Rena... Platinum-Resist... Recurrent Melan... Recurrent Renal... Refractory Mela... Refractory Rena... Sarcoma Stage IV Colore... Stage IV Ovaria... Stage IV Renal ...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02159989	Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So...	Sapanisertib Ziv-Aflibercept	18 Years -	National Cancer Institute (NCI)
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL	NCT04729725	Advanced Malign... Metastatic Mali... Unresectable Ma...	Anti-TGF-beta M... Cemiplimab	18 Years -	M.D. Anderson Cancer Center
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness	NCT05691491	Advanced Malign... Advanced Micros... Hematopoietic a... Metastatic Mali... Metastatic Micr... Stage III Color... Stage IV Colore...	Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Temozolomide Tuvusertib	18 Years -	National Cancer Institute (NCI)
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal	NCT05530759	Hematopoietic a... Metastatic Mali...	Biopsy Specimen Biospecimen Col... Biospecimen Col... Medical Chart R...	18 Years -	Mayo Clinic
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	NCT02503709	Advanced Malign... Metastatic Mali... Unresectable So...	CDK Inhibitor A... Laboratory Biom... Onalespib Pharmacological...	18 Years -	National Cancer Institute (NCI)
BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors	NCT05010096	Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig...	Copanlisib Elimusertib	18 Years -	M.D. Anderson Cancer Center
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer	NCT02321501	ALK Positive Locally Advance... Metastatic Mali... ROS1 Gene Rearr... Stage IIIB Lung... Stage IV Lung N...	Ceritinib Everolimus Laboratory Biom... Pharmacological...	18 Years -	M.D. Anderson Cancer Center
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery	NCT03184038	Metastatic Mali... Metastatic Mali...	Cognitive Asses... Stereotactic Ra... Stereotactic Bo... Quality-of-Life...	18 Years -	Thomas Jefferson University
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2	NCT03284385	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Stage III Renal... Stage IV Renal ...	Adavosertib	18 Years -	National Cancer Institute (NCI)
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers	NCT04021043	Advanced Malign... Metastatic Carc... Metastatic Carc... Metastatic Mali... Metastatic Mali...	Anti-GITR Agoni... Ipilimumab Nivolumab Stereotactic Bo...	18 Years -	M.D. Anderson Cancer Center
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	NCT05111561	Advanced Malign... Metastatic Mali... Refractory Mali... Triple-Negative... Unresectable Ma...	BET Bromodomain... Binimetinib Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Ipilimumab and Imatinib Mesylate in Advanced Cancer	NCT01738139	Advanced Malign... C-KIT Tyrosine ... Clinical Stage ... Metastatic Gast... Metastatic Mali... Metastatic Mela... Pathologic Stag... Unresectable Me... Unresectable So...	Imatinib Mesyla... Ipilimumab	15 Years -	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: